Search
Now showing items 1-3 of 3
Molecular mechanisms of PARP inhibitor sensitivity in primary triple negative breast cancer
(Institute of Cancer Research (University Of London), 2021-08-31)
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harbouring evidence of defective homologous recombination (HR) DNA repair. At present there are no biomarkers available in ...
Tracking the molecular and metabolic fingerprints of inhalational versus intravenous anaesthetics in preclinical models of breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Triplet combination of palbociclib, taselisib and fulvestrant and biomarkers for CDK4/6 and PI3-kinase inhibition in breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Targeting the commonly upregulated cell-cycle and PI3-kinase pathway in breast cancer are two of the most novel approaches to tackle the disease, with both strategies having led to clinically meaningful results and licensed ...